- Patients who were given two anti-clotting medications for thirty months after heart-stent placement were significantly less likely to develop blood clots within their stents or to have a heart attack than those with briefer treatment.
- This finding extends current clinical practice, since in the United States recommendations advise dual anti-clotting therapy for only 12 months after receiving stents.
CHICAGO — Patients who took two anti-clotting medications beyond the standard 12 months after stent placement were significantly less likely to develop blood clots within their stents or to have a heart attack than those whose treatment followed the standard 12 month protocol, according to late-breaking clinical trial research presented at the American Heart Association’s Scientific Sessions 2014.
“We know that dual antiplatelet therapy is essential for all patients receiving coronary stents to prevent blood clots within the stents (in-stent thrombosis). This study showed that the preventive benefit continues when the medications can be taken for more than one year,” said the study’s principal investigator and lead author, Laura Mauri, M.D., M.Sc.
Investigators found that study participants who took aspirin plus another type of anti-clotting medication (clopidogrel or prasugrel) – for 30 rather than 12 months after stent placement:
- were .5 times less likely to develop in-stent thrombos is than patients who received dual therapy for 12 months, followed by aspirin plus placebo for 18 months (placebo group) and
- had about half the risk of having new heart attacks compared to the placebo group.
“Overall the benefits of longer therapy were very consistent throughout the types of patients we studied, and outweighed the risks,” she said.
A stent is a thin, wire-mesh tube inserted into a blocked coronary artery to hold it open and restore blood flow. Although infrequent, one of the most serious risks after stent placement is the formation of a blood clot, either within the stent or in another blood vessel.
“The DAPT (Dual Antiplatelet Therapy) Study was the first and only study comparing durations of treatment with antiplatelet therapy that was adequately powered to detect a benefit on stent-related heart attacks,” said Mauri, who is an interventional cardiologist at Brigham and Women’s Hospital, associate professor of medicine at Harvard Medical School and Chief Scientific Adviser at the Harvard Clinical Research Institute in Boston, Massachusetts.
To prevent blood clots, standard post-stent treatment involves dual treatment with aspirin and another anti-clotting medication. European guidelines call for six to 12 months of this treatment and U.S. guidelines recommend it for 12 months after the procedure. What was unclear until now was whether extending this combined treatment for longer than 12 months could decrease the risk of in-stent thrombosis or whether it would prevent heart attack or stroke. The safety of longer-term treatment was also assessed in this trial.
Although moderate to severe bleeding was more common among the medication group than the placebo group in the study, fatal bleeding was rare among both groups of patients. While overall stroke rates and death rates were not reduced by extending the combined treatment, the investigators noted in a secondary analysis, including data beyond the time point after all patients had stopped the study drug (to 33 months), that death from any cause was 0.8 percent higher (2.3 percent vs, 1.5 percent) among the medication group compared to those on placebo. The study results were tracked during the study by a data safety monitoring committee, but this difference in risk was not evident until the end of the study, Mauri said.
A secondary analysis revealed that the higher death rate was attributable to trauma and cancer.
“However, there was no difference in the occurrence of new cancers,” Mauri said. “In retrospect, it appears that there may have been an imbalance between the groups in the number of patients with known cancer before enrollment in the study. Taken together with results from many other large studies of these medications, enrolling over 60,000 subjects worldwide, that show no difference in mortality, it seems likely that this finding was related to a chance imbalance between the groups studied in the trial.”
Prevention of heart attack and blood clots in stents with longer antiplatelet therapy was consistent in all patient groups, drug and stent types studied, Mauri noted, but “physicians should consider individual patient risks in prescribing dual anti-clotting therapy. In particular, the trial excluded patients with a history of major bleeding either before the stent procedure or within the first year of treatment.”
DAPT was a five-year, international study of 25,682 patients. 22,866 received drug-eluting stents, and of these 9,961 patients (average age 62, about 25 percent female, and mostly from the United States) were randomized in the primary analysis. The investigators randomly assigned patients to one of the two groups, and neither investigators nor patients knew who was receiving medication versus placebo. The study took place from August 2009, to June 2014, at more than 450 sites in the United States, Canada, Europe, Australia, and New Zealand.
Limitations of the study include the fact that it only included patients who were known to have tolerated anti-clotting medication for a year; and follow-up ended after 33 months, even though the study data suggest that a longer course of treatment may provide additional benefit.
Co- principal investigator Dean Kereiakes, M.D., will present the results comparing subjects treated with drug-eluting and bare metal stents in a Clinical Science Special Report session (abstract 20113) on Tuesday, Nov. 18, 2014 at the Scientific Sessions.
Other authors and author disclosures are on the manuscript. The Harvard Clinical Research Institute and the following stent and pharmaceutical companies supported the study: Abbott; Boston Scientific Corporation; Cordis Corporation; Medtronic, Inc.; Bristol-Myers Squibb Company/Sanofi Pharmaceuticals Partnership; Eli Lilly and Company; and Daiichi Sankyo Company Limited.
- For more news from the AHA’s Scientific Sessions follow us on Twitter @HeartNews #AHA14.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
Note: Actual presentation is 4:15 p.m., CT/5:15 p.m. ET, Sunday, Nov. 16, 2014.
Life is why we fund scientific breakthroughs that save and improve lives.